{"disease":{"id":"transitional-cell-carcinoma-of-the-bladder","name":"transitional cell carcinoma of the bladder"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07589413","title":"Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Zhiping Wang","has_results":false},{"nct_id":"NCT03263039","title":"Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT01828736","title":"Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","has_results":false},{"nct_id":"NCT05121948","title":"A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"HiberCell, Inc.","has_results":false},{"nct_id":"NCT01954173","title":"Adjuvant Radiation for High Risk Bladder Cancer","phase":"NA","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT01382706","title":"Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT03430895","title":"Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT03081858","title":"Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Lipac Oncology LLC","has_results":true},{"nct_id":"NCT02723838","title":"Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Oncolytics Biotech","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}